Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. A, 97-105
© 1999 The British Society for Antimicrobial Chemotherapy
Infectious exacerbations of chronic bronchitis: diagnosis and management
Medical Research 151, Infectious Disease Division, Buffalo VA Medical Center, 3495 Bailey Avenue, Buffalo, NY 14215, USA
Chronic bronchitis is an increasing cause of significant morbidity and mortality. Despite treatment, respiratory tract infection is the most common identifiable cause of death for patients with chronic obstructive pulmonary disease. Repeated infectious exacerbations may ultimately cause acute and chronic lung injury. The most common bacterial aetiologies of acute exacerbations of chronic bronchitis (AECB) include Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae. Pseudomonas aeruginosa is often a nosocomial pathogen and is becoming more prevalent in patients with severe underlying disease. Viruses are responsible for approximately one-third of acute exacerbations overall. Atypical pathogens are causative pathogens in <10% of episodes. The diagnosis of AECB is often based on clinical impression, although suspicion of bacterial infection can be enhanced by quantitative Gram's stains from appropriately obtained sputum specimens. However, a specific microbiological diagnosis is only needed in certain specific situations. Management of AECB involves non-drug interventions (e.g. smoking cessation) and antibiotic treatment. Recommendations for antibiotic use in patients with known or highly suspected AECB are still evolving. The selection of an antibiotic for treatment of an infectious episode must consider underlying patient co-morbidities, likely pathogens, resistance issues and individual antibiotic properties. Cephalosporins, ß-lactam/ß-lactamase inhibitor combinations and macrolides are all reasonable choices. However, due to the increasing prevalence of resistance to standard antibiotics among common respiratory pathogens, and increased incidence of Pseudomonas spp., fluoroquinolones should be a first-line treatment for AECB in patients who have chronic bronchitis complicated by co-morbid illness, severe obstruction (FEV 1 < 50%), old age (>65 years) or have recurrent exacerbations. In patients who do not have these risk factors (i.e. those with simple chronic bronchitis), agents such as co-trimoxazole remain useful.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Pasqua, G. Biscione, G. Crigna, and M. Cazzola Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 209 - 214. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Sener, F. Tunckanat, S. Ulusoy, A. Tunger, G. Soyletir, L. Mulazimoglu, N. Gurler, L. Oksuz, I. Koksal, K. Aydin, et al. A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005 J. Antimicrob. Chemother., September 1, 2007; 60(3): 587 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Gorse, T. Z. O'Connor, S. L. Young, M. P. Habib, J. Wittes, K. M. Neuzil, and K. L. Nichol Impact of a Winter Respiratory Virus Season on Patients With COPD and Association With Influenza Vaccination. Chest, October 1, 2006; 130(4): 1109 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Amsden, I. M. Baird, S. Simon, and G. Treadway Efficacy and Safety of Azithromycin vs Levofloxacin in the Outpatient Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis Chest, March 1, 2003; 123(3): 772 - 777. [Abstract] [Full Text] [PDF]
|
|